Skip to Content

Generic Kyprolis Availability

Kyprolis is a brand name of carfilzomib, approved by the FDA in the following formulation(s):

KYPROLIS (carfilzomib - powder;intravenous)

  • Manufacturer: ONYX THERAP
    Approval date: July 20, 2012
    Strength(s): 60MG/VIAL [RLD]
  • Manufacturer: ONYX THERAP
    Approval date: June 3, 2016
    Strength(s): 30MG/VIAL

Has a generic version of Kyprolis been approved?

No. There is currently no therapeutically equivalent version of Kyprolis available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Kyprolis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compounds for enzyme inhibition
    Patent 7,232,818
    Issued: June 19, 2007
    Inventor(s): Smyth; Mark S. & Laidig; Guy J. & Borchardt; Ronald T. & Bunin; Barry A. & Crews; Craig M. & Musser; John H.
    Assignee(s): Proteolix, Inc.
    Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Patent expiration dates:
    • April 14, 2025
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Compounds for enzyme inhibition
    Patent 7,417,042
    Issued: August 26, 2008
    Inventor(s): Smyth; Mark S. & Laidig; Guy J.
    Assignee(s): Proteolix, Inc.
    Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Patent expiration dates:
    • July 20, 2026
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Compounds for enzyme inhibition
    Patent 7,491,704
    Issued: February 17, 2009
    Inventor(s): Smyth; Mark S. & Laidig; Guy J. & Borchardt; Ronald T. & Bunin; Barry A. & Crews; Craig M. & Musser; John H.
    Assignee(s): Proteolix, Inc.
    Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Patent expiration dates:
    • April 14, 2025
      ✓ 
      Patent use: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
  • Composition for enzyme inhibition
    Patent 7,737,112
    Issued: June 15, 2010
    Inventor(s): Lewis; Evan R. & Ho; Mark Nguyen & Fonseca; Fabiana N.
    Assignee(s): Onyx Therapeutics, Inc.
    Compositions comprising one or more practically insoluble proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin, substantially increase the solubility of these proteasome inhibitors and facilitate their administration. Such compositions optionally comprise a buffer. Methods of treatment using such compositions are also disclosed.
    Patent expiration dates:
    • December 7, 2027
      ✓ 
      Drug product
  • Compounds for enzyme inhibition
    Patent 8,129,346
    Issued: March 6, 2012
    Inventor(s): Smyth; Mark S. & Laidig; Guy J. & Borchardt; Ronald T. & Bunin; Barry A. & Crews; Craig M. & Musser; John H.
    Assignee(s): Onyx Therapeutics, Inc.
    Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Patent expiration dates:
    • April 14, 2025
      ✓ 
      Patent use: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
  • Compounds for enzyme inhibition
    Patent 8,207,125
    Issued: June 26, 2012
    Inventor(s): Smyth; Mark S. & Laidig; Guy J.
    Assignee(s): Onyx Therapeutics, Inc.
    Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Patent expiration dates:
    • April 14, 2025
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Compounds for enzyme inhibition
    Patent 8,207,126
    Issued: June 26, 2012
    Inventor(s): Smyth; Mark S. & Laidig; Guy J.
    Assignee(s): Onyx Therapeutics, Inc.
    Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Patent expiration dates:
    • April 14, 2025
      ✓ 
      Drug product
  • Compounds for enzyme inhibition
    Patent 8,207,127
    Issued: June 26, 2012
    Inventor(s): Smyth; Mark S. & Laidig; Guy J.
    Assignee(s): Onyx Technologies, Inc.
    Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Patent expiration dates:
    • April 14, 2025
      ✓ 
      Patent use: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
  • Compounds for enzyme inhibition
    Patent 8,207,297
    Issued: June 26, 2012
    Inventor(s): Smyth; Mark S. & Laidig; Guy J.
    Assignee(s): Onyx Therapeutics, Inc.
    Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Patent expiration dates:
    • April 14, 2025
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 20, 2017 - NEW CHEMICAL ENTITY
    • July 24, 2018 - EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THEREPY
    • January 21, 2019 - REVISED INDICATION FOR USE IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY.
    • January 21, 2019 - AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
    • July 20, 2019 - ORPHAN DRUG EXCLUSIVITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide